Are drug ads a waste of money?

DTC ads work. That's the conventional wisdom--and the reason why U.S. drugmakers spent about $3.7 billion on them last year. But a new Harvard Medical School study, the first controlled study of DTC ads, challenges that belief. In fact, the study authors found that DTC advertising might be a waste of money.

Researchers went to Canada, which doesn't allow drugmakers to advertise to consumers. Canadians are, however, exposed to plenty of American media, and along with it, drug ads. Except for residents of Quebec, that is. In that French-speaking province most people get their TV fix from French-language media.

Comparing sales of the arthritis med Enbrel, allergy spray Nasonex, and irritable bowel drug Zelnorm (which has since been withdrawn) in English-speaking areas and in Quebec, the study found little change after major ad campaigns. A $194 million Enbrel campaign and $235 million Nasonex push failed to boost sales in the English-speaking provinces; scrip patterns were identical before and after ads ran. Zelnorm sales did leap by 40 percent in the English-speaking areas as its ad campaign began, but the effect quickly wore off, and sales patterns resumed their pre-ad appearance.

If this study is accurate, the good news is that all the ethical worries about DTC ads are baseless. The bad news is that ad spending may just be billions down the drain.

- read the story in the Washington Post
- check out Forbes' take
- see the U.S. News article

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.